We continue to seek value-generating partnerships, including with large biotechnology and pharmaceutical companies with late stage development and commercialization capabilities, to leverage our internal capabilities, both within and outside the field of oncology. Our ability to build collaborations is exemplified by our collaborations with Shire (immuno-oncology) and Genentech (infectious diseases).
For business development inquiries, please contact:
Mia Wæver Midena, M.Sc.
Director, Business Development
What we do
Symphogen is a clinical-stage antibody oncology-focused company with a differentiated product pipeline and significant commercial opportunities. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations.
Our current strategy is to develop innovative therapies for the treatment of cancer and other significant diseases using our unique mAb platform. Cancer is our focus while other diseases are currently pursued through partnerships.
Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb products candidates and we own the global development and commercialization rights to Sym004, Sym013 and Sym015. Each of these clinical product candidates has the potential to provide meaningful treatment options for cancer patients that are not currently available.
We apply our novel multi-targeting approach for receptor tyrosine kinases and our superior mAb research platform to create differentiated product candidates to treat cancer and other significant diseases.